Market Opportunity

Pharmaceutical and biotech companies are under increasing pressure to drive innovation and cut costs of their research and development efforts. Many companies are moving towards "virtual" R&D models and outsourcing programs to clinical research organizations (CROs). Industry leading companies such as sanofi aventis and Pfizer are positioning CROs at the center of the their business strategy with a goal of driving innovation  while reducing costs.

Additionally, there continues to be a growing need for better therapeutic targets for cancer treatments. Our CellSelect technology platform helps our partners rapidly and effectively advance compounds into anti-cancer drug development. We identify important clinical benefits through our screening and monitoring of the activity of diseases or by assessing therapeutic response working with partners through the end of Phase 2 clinical development.

BerGenBio is a powerful partner for pharmaceutical companies seeking to derisk their R&D programs and minimize the cost of internal R&D efforts. Our focus and expertise in cancer biology helps our partners make cancer drug development more cost efficient while optimizing clinical results.